Tyrosine kinase inhibitors (TKIs) inhibit the disease-defining BCR::ABL1 fusion kinase, are highly effective for chronic myeloid leukemia (CML), and have revolutionized its treatment. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.